Given the remarkable similarities in the immunosuppressive mechanisms active in both disorders [15] and the excellent safety profile of OX-40 ligand, we believe that OX-40 ligand should also be investigated as a potential immuno-adjuvant in patients with sepsis due to MDR bacteria. This evidence concerns the gene TNFRSF4 and Sepsis.